Philip W. Kantoff, MD

Publications

• Sun T, Mary LG, Oh WK, Freedman ML, Pomerantz M, Pienta KJ, Kantoff PW.Inherited Variants in the Chemokine CCL2 Gene and Prostate Cancer Aggressiveness in a Caucasian Cohort.Clin Cancer Res. 2011 Mar 15;17(6):1546-52.
  21135144
• Misra D, Xie W, Regan MM, Ross RW, Lee GS, Germain D, Kantoff PW, Oh WK.Germline CAG repeat length of the androgen receptor and time to progression in patients with prostate cancer treated with androgen deprivation therapy.BJU Int. 2011 Mar 16.
  21410629
• Pomerantz M, Werner L, Xie W, Regan MM, Lee GS, Sun T, Evan C, Petrozziello G, Nakabayashi M, Oh WK, Kantoff PW, Freedman ML.Association of prostate cancer risk loci with disease aggressiveness and prostate cancer-specific mortality.Cancer Prev Res (Phila
  21367958
• Berger MF, Lawrence MS, Demichelis F, Drier Y, Cibulskis K, Sivachenko AY, Sboner A, Esgueva R, Pflueger D, Sougnez C, Onofrio R, Carter SL, Park K, Habegger L, Ambrogio L, Fennell T, Parkin M, Saksena G, Voet D, Ramos AH, Pugh TJ, Wilkinson J, Fisher S,
  21307934
• Abe M, Xie W, Regan MM, King IB, Stampfer MJ, Kantoff PW, Oh WK, Chan JM.Single-nucleotide polymorphisms within the antioxidant defence system and associations with aggressive prostate cancer.BJU Int. 2011 Jan;107(1):126-134.
  20477822
• Drzymalski DM, Oh WK, Werner L, Regan MM, Kantoff P, Tuli S.Predictors of survival in patients with prostate cancer and spinal metastasis. Presented at the 2009 Joint Spine Section Meeting. Clinical article.J Neurosurg Spine. 2010 Dec;13(6):789-94.
  21121759
• Hayes JH, Ollendorf DA, Pearson SD, Barry MJ, Kantoff PW, Stewart ST, Bhatnagar V, Sweeney CJ, Stahl JE, McMahon PM.Active surveillance compared with initial treatment for men with low-risk prostate cancer: a decision analysis.JAMA. 2010 Dec 1;304(21):237
  21119084
• Cho E, Curhan G, Hankinson SE, Kantoff P, Atkins MB, Stampfer M, Choueiri TK.Prospective evaluation of analgesic use and risk of renal cell cancer.J Clin Oncol..
• Pomerantz MM, Shrestha Y, Flavin RJ, Regan MM, Penney KL, Mucci LA, Stampfer MJ, Hunter DJ, Chanock SJ, Schafer EJ, Chan JA, Tabernero J, Baselga J, Richardson AL, Loda M, Oh WK, Kantoff PW, Hahn WC, Freedman ML.Analysis of the 10q11 cancer risk locus imp
  21085629
• Penney KL, Pyne S, Schumacher FR, Sinnott JA, Mucci LA, Kraft PL, Ma J, Oh WK, Kurth T, Kantoff PW, Giovannucci EL, Stampfer MJ, Hunter DJ, Freedman ML.Genome-Wide Association Study of Prostate Cancer Mortality.Cancer Epidemiol Biomarkers Prev. 2010 Nov;1
  20978177
• Sun T, Lee GS, Oh WK, Pomerantz M, Yang M, Xie W, Freedman ML, Kantoff PW.Single-Nucleotide Polymorphisms in p53 Pathway and Aggressiveness of Prostate Cancer in a Caucasian Population.Clin Cancer Res. 2010 Nov 1;16(21):5244-51.
  20855462
• Berger MF, Lawrence MS, Demichelis F, Cibulskis K, Sivachenko A, Sboner A, Esgueva R, Pflueger D, Sougnez C, Onofrio R, Carter S, Drier Y, Ambrogio L, Fenne T, Parkin M, Gordon S, Voet D, Ramos A, Pugh T, Wilkinson J, Fisher S, Winckler W, Mahan S, Ardlie
• Oh WK, Vargas R, Jacobus S, Leitzel K, Regan MM, Hamer P, Pierce K, Brown-Shimer S, Carney W, Ali SM, Kantoff PW, Lipton A.Elevated plasma tissue inhibitor of metalloproteinase-1 levels predict decreased survival in castration-resistant prostate cancer pa
  20862742
• Kantoff PW, Higano CS, Shore ND, Berger ER, Small EJ, Penson DF, Redfern CH, Ferrari AC, Dreicer R, Sims RB, Xu Y, Frohlich MW, Schellhammer PF, .Sipuleucel-T immunotherapy for castration-resistant prostate cancer.N Engl J Med. 2010 Jul 29;363(5):411-22.
  20818862
• Sun T, Lee GS, Werner L, Pomerantz M, Oh WK, Kantoff PW, Freedman ML.Inherited variations in AR, ESR1, and ESR2 genes are not associated with prostate cancer aggressiveness or with efficacy of androgen deprivation therapy.Cancer Epidemiol Biomarkers Prev.
  20615892
• Nguyen PL, Chen MH, Beard CJ, Suh WW, Renshaw AA, Loffredo M, McMahon E, Kantoff PW, D'Amico AV.Radiation With or Without 6 Months of Androgen Suppression Therapy in Intermediate- and High-Risk Clinically Localized Prostate Cancer: A Postrandomization
  19864082
• Nguyen PL, Chen MH, Choueiri TK, Hoffman KE, Hu JC, Martin NE, Beard CJ, Dosoretz DE, Moran BJ, Katin MJ, Braccioforte MH, Ross R, Salenius SA, Kantoff PW, D'Amico AV.Risk of All-Cause and Prostate Cancer-Specific Mortality After Brachytherapy in Men
  20605366
• Higano CS, Small EJ, Schellhammer P, Yasothan U, Gubernick S, Kirkpatrick P, Kantoff PW.Sipuleucel-T.Nat Rev Drug Discov. 2010 Jul;9(7):513-4.
  20592741
• Nakabayashi M, Oh WK, Jacobus S, Regan MM, Taplin ME, Kantoff PW, Rosenberg JE.Activity of ketoconazole after taxane-based chemotherapy in castration-resistant prostate cancer.BJU Int. 2010 May;105(10):1392-6.
  19863532
• Penney KL, Schumacher FR, Li H, Kraft P, Morris JS, Kurth T, Mucci LA, Hunter DJ, Kantoff PW, Stampfer MJ, Ma J.A large prospective study of SEP15 genetic variation, interaction with plasma selenium levels, and prostate cancer risk and survival.Cancer Pre
  20424130
• Fiorentino M, Judson G, Penney K, Flavin R, Stark J, Fiore C, Fall K, Martin N, Ma J, Sinnott J, Giovannucci E, Stampfer M, Sesso HD, Kantoff PW, Finn S, Loda M, Mucci L.Immunohistochemical expression of BRCA1 and lethal prostate cancer.Cancer Res. 2010 A
  20388772
• Wang AZ, Yuet K, Zhang L, Gu FX, Huynh-Le M, Radovic-Moreno AF, Kantoff PW, Bander NH, Langer R, Farokhzad OC.ChemoRad nanoparticles: a novel multifunctional nanoparticle platform for targeted delivery of concurrent chemoradiation.Nanomed. 2010 Apr;5(3):3
  20394530
• Ryan CJ, Smith MR, Fong L, Rosenberg JE, Kantoff P, Raynaud F, Martins V, Lee G, Kheoh T, Kim J, Molina A, Small EJ.Phase I Clinical Trial of the CYP17 Inhibitor Abiraterone Acetate Demonstrating Clinical Activity in Patients With Castration-Resistant Pro
  20159824
• Sboner A, Demichelis F, Calza S, Pawitan Y, Setlur SR, Hoshida Y, Perner S, Adami HO, Fall K, Mucci LA, Kantoff PW, Stampfer M, Andersson SO, Varenhorst E, Johansson JE, Gerstein MB, Golub TR, Rubin MA, Andren O.Molecular sampling of prostate cancer: a di
  20233430
• Kantoff PW, Schuetz TJ, Blumenstein BA, Glode LM, Bilhartz DL, Wyand M, Manson K, Panicali DL, Laus R, Schlom J, Dahut WL, Arlen PM, Gulley JL, Godfrey WR.Overall survival analysis of a phase II randomized controlled trial of a Poxviral-based PSA-targeted
  20100959
• Mohler J, Bahnson RR, Boston B, Busby JE, D'Amico A, Eastham JA, Enke CA, George D, Horwitz EM, Huben RP, Kantoff P, Kawachi M, Kuettel M, Lange PH, Macvicar G, Plimack ER, Pow-Sang JM, Roach M, Rohren E, Roth BJ, Shrieve DC, Smith MR, Srinivas S, Twa
  20141676
• Nguyen PL, Chen MH, Beard CJ, Suh WW, Choueiri TK, Efstathiou JA, Hoffman KE, Loffredo M, Kantoff PW, D'Amico AV.Comorbidity, body mass index, and age and the risk of nonprostate-cancer-specific mortality after a postradiation prostate-specific antige
  19957321
• Nguyen PL,Chen MH,Renshaw AA,Loffredo M,Kantoff PW,D'Amico AV.Survival Following Radiation and Androgen Suppression Therapy for Prostate Cancer in Healthy Older Men: Implications for Screening Recommendations.Int J Radiat Oncol Biol Phys. 2010 Feb 1;7
  19395186
• Smith MR, Kantoff PW.Changes in PSA kinetics after DNA vaccine therapy-not so fast!.J Clin Oncol. 2010 Feb 1;28(4):e58; author reply e59.
  20008614
• Wo JY, Chen MH, Nguyen PL, Renshaw AA, Loffredo MJ, Kantoff PW, D'Amico AV.Evaluating the Combined Effect of Comorbidity and Prostate-Specific Antigen Kinetics on the Risk of Death in Men After Prostate-Specific Antigen Recurrence.J Clin Oncol. 2009 D
  19858385
• Taplin ME, Regan MM, Ko YJ, Bubley GJ, Duggan SE, Werner L, Beer TM, Ryan CW, Mathew P, Tu SM, Denmeade SR, Oh WK, Sartor O, Mantzoros CS, Rittmaster R, Kantoff PW, Balk SP.Phase II study of androgen synthesis inhibition with ketoconazole, hydrocortisone,
  19887483
• Sartor O, Nakabayashi M, Taplin ME, Ross RW, Kantoff PW, Balk SP, Oh WK.Activity of dutasteride plus ketoconazole in castration-refractory prostate cancer after progression on ketoconazole alone.Clin Genitourin Cancer. 2009 Oct;7(3):E90-2.
  19815488
• D'Amico AV,Chen MH,Renshaw AA,Loffredo M,Kantoff PW.Interval to Testosterone Recovery After Hormonal Therapy for Prostate Cancer and Risk of Death.Int J Radiat Oncol Biol Phys. 2009 Sep 1;75(1):10-5.
  19395184
• Jia L, Landan G, Pomerantz M, Jaschek R, Herman P, Reich D, Yan C, Khalid O, Kantoff P, Oh W, Manak JR, Berman BP, Henderson BE, Frenkel B, Haiman CA, Freedman M, Tanay A, Coetzee GA.Functional enhancers at the gene-poor 8q24 cancer-linked locus.PLoS Gene
  19680443
• Sun T, Yang M, Kantoff P, Lee GS.Role of microRNA-221/-222 in cancer development and progression.Cell Cycle. 2009 Aug;8(15):2315-6.
  19625765
• Chan JM, Oh WK, Xie W, Regan MM, Stampfer MJ, King IB, Abe M, Kantoff PW.Plasma selenium, manganese superoxide dismutase, and intermediate- or high-risk prostate cancer.J Clin Oncol. 2009 Aug 1;27(22):3577-83.
  19528373
• Wang Q, Li W, Zhang Y, Yuan X, Xu K, Yu J, Chen Z, Beroukhim R, Wang H, Lupien M, Wu T, Regan MM, Meyer CA, Carroll JS, Manrai AK, Jänne OA, Balk SP, Mehra R, Han B, Chinnaiyan AM, Rubin MA, True L, Fiorentino M, Fiore C, Loda M, Kantoff PW, Liu XS, Brow
  19632176
• Mucci LA,Stark JR,Figg WD,Schumacher F,Li H,Abe M,Hennessy K,Stampfer MJ,Gaziano JM,Ma J,Kantoff PW.Polymorphism in endostatin, an angiogenesis inhibitor, and prostate cancer risk and survival: A prospective study.Int J Cancer. 2009 Sep 1;125(5):1143-6.
  19431146
• Pomerantz MM, Beckwith CA, Regan MM, Wyman SK, Petrovics G, Chen Y, Hawksworth DJ, Schumacher FR, Mucci L, Penney KL, Stampfer MJ, Chan JA, Ardlie KG, Fritz BR, Parkin RK, Lin DW, Dyke M, Herman P, Lee S, Oh WK, Kantoff PW, Tewari M, McLeod DG, Srivastava
  19549893
• Sun T, Wang Q, Balk S, Brown M, Lee GS, Kantoff P.The role of microRNA-221 and microRNA-222 in androgen-independent prostate cancer cell lines.Cancer Res. 2009 Apr 15;69(8):3356-63.
  19351832
• Penney KL,Salinas CA,Pomerantz M,Schumacher FR,Beckwith CA,Lee GS,Oh WK,Sartor O,Ostrander EA,Kurth T,Ma J,Mucci L,Stanford JL,Kantoff PW,Hunter DJ,Stampfer MJ,Freedman ML.Evaluation of 8q24 and 17q risk loci and prostate cancer mortality.Clin Cancer Res.
  19366828
• Lee TH,Kantoff PW,McNaughton-Collins MF.Screening for prostate cancer.N Engl J Med. 2009 Mar 26;360(13):e18.
  19297563
• Choueiri TK,Xie W,D'Amico AV,Ross RW,Hu JC,Pomerantz M,Regan MM,Taplin ME,Kantoff PW,Sartor O,Oh WK.Time to prostate-specific antigen nadir independently predicts overall survival in patients who have metastatic hormone-sensitive prostate cancer treat
  19152438
• D'Amico AV,Chen MH,Renshaw AA,Loffredo M,Kantoff PW.Causes of death in men undergoing androgen suppression therapy for newly diagnosed localized or recurrent prostate cancer.Cancer. 2008 Dec 15;113(12):3290-7.
  18980297
• Wang AZ,Bagalkot V,Vasilliou CC,Gu F,Alexis F,Zhang L,Shaikh M,Yuet K,Cima MJ,Langer R,Kantoff PW,Bander NH,Jon S,Farokhzad OC.Superparamagnetic iron oxide nanoparticle-aptamer bioconjugates for combined prostate cancer imaging and therapy.ChemMedChem. 20
  18613203
• Mucci LA,Pawitan Y,Demichelis F,Fall K,Stark JR,Adami HO,Andersson SO,Andren O,Eisenstein A,Holmberg L,Huang W,Kantoff PW,Kim R,Perner S,Stampfer MJ,Johansson JE,Rubin MA.Testing a multigene signature of prostate cancer death in the Swedish Watchful Waiti
  18583469
• D'Amico AV,Chen MH,Renshaw AA,Loffredo B,Kantoff PW.Risk of prostate cancer recurrence in men treated with radiation alone or in conjunction with combined or less than combined androgen suppression therapy.J Clin Oncol. 2008 Jun 20;26(18):2979-83.
  18565884
• Tomlins S, Rhodes D, Yu J; Varambally S; Mehra R, Perner S, Demichelis F, Helgeson B, Laxman B, Morris D, Cao Q, Cao X, Andren O, Fall K; Johnson L, Wei J, Shah R, Al-Ahmadie H, Eastham J, Eggener S, Fine S, Hotakainen K, Stenman U, Tsodikov A, Gerald W,
• Setlur SR,Mertz KD,Hoshida Y,Demichelis F,Lupien M,Perner S,Sboner A,Pawitan Y,Andren O,Johnson LA,Tang J,Adami HO,Calza S,Chinnaiyan AM,Rhodes D,Tomlins S,Fall K,Mucci LA,Kantoff PW,Stampfer MJ,Andersson SO,Varenhorst E,Johansson JE,Brown M,Golub TR,Rubi
  18505969
• Halabi S,Vogelzang NJ,Kornblith AB,Ou SS,Kantoff PW,Dawson NA,Small EJ.Pain predicts overall survival in men with metastatic castration-refractory prostate cancer.J Clin Oncol. 2008 May 20;26(15):2544-9.
  18487572
• Arlen PM, Bianco F, Dahut WL, D'Amico A, Figg WD, Freedland SJ, Gulley JL, Kantoff PW, Kattan MW, Lee A, Regan MM, Sartor O.Prostate specific antigen working group guidelines on prostate specific antigen doubling time.J Urol. 2008 Jun;179(6):2181-6.
  18423743
• Taplin ME, Manola J, Oh WK, Kantoff PW, Bubley GJ, Smith M, Barb D, Mantzoros C, Gelmann EP, Balk SP.A phase II study of mifepristone (RU-486) in castration-resistant prostate cancer, with a correlative assessment of androgen-related hormones.BJU Int. 200
  18399827
• Scher HI, Halabi S, Tannock I, Morris M, Sternberg CN, Carducci MA, Eisenberger MA, Higano C, Bubley GJ, Dreicer R, Petrylak D, Kantoff P, Basch E, Kelly WK, Figg WD, Small EJ, Beer TM, Wilding G, Martin A, Hussain M.Design and end points of clinical tria
  18309951
• Dall'Era MA, Cooperberg MR, Chan JM, Davies BJ, Albertsen PC, Klotz LH, Warlick CA, Holmberg L, Bailey DE Jr, Wallace ME, Kantoff PW, Carroll PR.Active surveillance for early-stage prostate cancer: review of the current literature.Cancer. 2008 Apr 15;
  18306379
• Bao BY,Chuang BF,Wang Q,Sartor O,Balk SP,Brown M,Kantoff PW,Lee GS.Androgen receptor mediates the expression of UDP-glucuronosyltransferase 2 B15 and B17 genes.Prostate. 2008 Jun 1;68(8):839-48.
  18302198
• D'Amico AV, Halabi S, Vollmer R, Loffredo M, McMahon E, Sanford B, Archer L, Vogelzang NJ, Small EJ, Kantoff PW.p53 protein expression status and recurrence in men treated with radiation and androgen suppression therapy for higher-risk prostate cancer
  18291508
• Ross RW, Xie W, Regan MM, Pomerantz M, Nakabayashi M, Daskivich TJ, Sartor O, Taplin ME, Kantoff PW, Oh WK.Efficacy of androgen deprivation therapy (ADT) in patients with advanced prostate cancer: association between Gleason score, prostate-specific antig
  18293426
• Ross RW, Oh WK, Xie W, Pomerantz M, Nakabayashi M, Sartor O, Taplin ME, Regan MM, Kantoff PW, Freedman M.Inherited variation in the androgen pathway is associated with the efficacy of androgen-deprivation therapy in men with prostate cancer.J Clin Oncol.
  18281655
• D'Amico AV, Chen MH, Renshaw AA, Loffredo M, Kantoff PW.Androgen suppression and radiation vs radiation alone for prostate cancer: a randomized trial.JAMA. 2008 Jan 23;299(3):289-95.
  18212313
• Mucci LA, Pawitan Y, Demichelis F, Fall K, Stark JR, Adami HO, Andersson SO, Andrén O, Eisenstein AS, Holmberg L, Huang W, Kantoff PW, Perner S, Stampfer MJ, Johansson JE, Rubin MA.Nine-gene molecular signature is not associated with prostate cancer death
  18199732
• Nakabayashi M, Sartor O, Jacobus S, Regan MM, McKearn D, Ross RW, Kantoff PW, Taplin ME, Oh WK.Response to docetaxel/carboplatin-based chemotherapy as first- and second-line therapy in patients with metastatic hormone-refractory prostate cancer.BJU Int. 2
  18184327
• D'Amico AV, Kantoff PW, Chen MH.Aspirin and hormone therapy for prostate cancer.N Engl J Med. 2007 Dec 27;357(26):2737-8.
  18160699
• Corsello SM, Kantoff PW.Does androgen deprivation therapy in men with prostate cancer increase cardiovascular morbidity?.Nat Clin Pract Urol. 2008 Feb;5(2):80-1.
  18087294
• McIntyre MH, Kantoff PW, Stampfer MJ, Mucci LA, Parslow D, Li H, Gaziano JM, Abe M, Ma J.Prostate cancer risk and ESR1 TA, ESR2 CA repeat polymorphisms.Cancer Epidemiol Biomarkers Prev. 2007 Nov;16(11):2233-6.
  18006911
• Keller ET, Rowley DR, Tomlins SA, Drake CG, Kantoff PW, Pienta KJ, Montie JE, Carter HB, Hruszkewicz AM, Gomez J, Mohla S, Getzenberg RH.Eleventh Prouts Neck Meeting on Prostate Cancer: emerging strategies in prostate cancer therapy.Cancer Res. 2007 Oct 1
  17928375
• Avigan DE, Vasir B, George DJ, Oh WK, Atkins MB, McDermott DF, Kantoff PW, Figlin RA, Vasconcelles MJ, Xu Y, Kufe D, Bukowski RM.Phase I/II study of vaccination with electrofused allogeneic dendritic cells/autologous tumor-derived cells in patients with s
  17893567
• Bagalkot V, Zhang L, Levy-Nissenbaum E, Jon S, Kantoff PW, Langer R, Farokhzad OC.Quantum dot-aptamer conjugates for synchronous cancer imaging, therapy, and sensing of drug delivery based on bi-fluorescence resonance energy transfer.Nano Lett. 2007 Oct;7
  17854227
• Mosquera JM, Pawitan Y, Lee C, Adami HO, Mucci LA, Kantoff PW, Andersson SO, Chinnaiyan AM, Johansson JE, Rubin MA. .TMPRSS2:ERG Gene Fusion Associated with Lethal Prostate Cancer in a Watchful Waiting Cohort.Oncogene. 07/23/2007;38(26):1-7.
• Ross RW, Kantoff PW.Predicting outcomes in prostate cancer: how many more nomograms do we need?.J Clin Oncol. 2007 Aug 20;25(24):3563-4.
  17704399
• Mohler J, Babaian RJ, Bahnson RR, Boston B, D'Amico A, Eastham JA, Hauke RJ, Huben RP, Kantoff P, Kawachi M, Kuettel M, Lange PH, Logothetis C, MacVicar G, Pollack A, Pow-Sang JM, Roach M 3rd, Sandler H, Shrieve D, Srinivas S, Twardowski P, Urban DA,
  17692170
• Hayes JH, Barry MJ, Kantoff PW, Stahl JE.Prostate-specific antigen screening for prostate cancer: a decision-analytical perspective.BJU Int. 2007 Sep;100(3):486-8.
  17669139
• Cooperberg MR, Broering JM, Kantoff PW, Carroll PR.Contemporary trends in low risk prostate cancer: risk assessment and treatment.J Urol. 2007 Sep;178(3 Pt 2):S14-9.
  17644125
• Park Y, Downing SR, Kim D, Hahn WC, Li C, Kantoff PW, Wei LJ.Simultaneous and exact interval estimates for the contrast of two groups based on an extremely high dimensional variable: Application to Mass Spec data.Bioinformatics. 2007 Jun 15;23(12):1451-8.
  17459967
• Demichelis F, Fall K, Perner S, Andrén O, Schmidt F, Setlur SR, Hoshida Y, Mosquera JM, Pawitan Y, Lee C, Adami HO, Mucci LA, Kantoff PW, Andersson SO, Chinnaiyan AM, Johansson JE, Rubin MA.TMPRSS2:ERG gene fusion associated with lethal prostate cancer in
  17237811
• D'Amico AV, Goldhaber SZ; Chen MH, Loffredo M, RN, Renshaw AA, Loffredo B; PW Kantoff.Hormonal Therapy for Prostate Cancer and the Time Course to Cardiovascular Death.J Clin Oncol. 06/10/2007;17(25):2420-5.
• Pomerantz MM, Freedman ML, Kantoff PW.Genetic determinants of prostate cancer risk.BJU Int. 2007 Aug;100(2):241-3.
  17542988
• Pomerantz M, Manola J, Taplin ME, Bubley G, Inman M, Lowell J, Beard C, Kantoff PW, Oh WK.Phase II study of low dose and high dose conjugated estrogen for androgen independent prostate cancer.J Urol. 2007 Jun;177(6):2146-50.
  17509304
• Michaelson MD, Kaufman DS, Lee H, McGovern FJ, Kantoff PW, Fallon MA, Finkelstein JS, Smith MR.Randomized controlled trial of annual zoledronic acid to prevent gonadotropin-releasing hormone agonist-induced bone loss in men with prostate cancer.J Clin Onc
  17369566
• Oh WK, Hayes J, Evan C, Manola J, George DJ, Waldron H, Donovan M, Varner J, Orechia J, Katcher B, Lu D, Nevins A, Wright RL, Tormey L, Talcott J, Rubin MA, Loda M, Sellers WR, Richie JP, Kantoff PW, Weeks J.Development of an integrated prostate cancer re
  16859581
• Smith MR, Manola J, Kaufman DS, Oh WK, Bubley GJ, Kantoff PW.Celecoxib versus placebo for men with prostate cancer and a rising serum prostate-specific antigen after radical prostatectomy and/or radiation therapy.J Clin Oncol. 2006 Jun 20;24(18):2723-8.
  16782912
• Farokhzad OC, Cheng J, Teply BA, Sherifi I, Jon S, Kantoff PW, Richie JP, Langer R.Targeted nanoparticle-aptamer bioconjugates for cancer chemotherapy in vivo.Proc Natl Acad Sci U S A. 2006 Apr 18;103(16):6315-20.
  16606824
• Li H, Kantoff PW, Giovannucci E, Leitzmann M, Gaziano JM, Stampfer MJ, Ma J.Manganese Superoxide Dismutase (MnSOD) Polymorphism, Prediagnostic Plasma Antioxidants and Prostate Cancer Risk.Cancer Res.:In press.
• George D, Halabi S, Shepard TF, Sanford B, Vogelzang NJ, Small EJ, Kantoff PW.The Prognostic Significance of Plasma Interleukin-6 (IL-6) Levels in Patients with Metastatic Hormone-Refractory Prostate Cancer (HRCaP): Results from CALGB 9480.Clinical Cancer
• Taplin ME, George DJ, Halabi S, Sanford B, Febbo PG, Hennessy KT, Mihos CG, Vogelzang NJ, Small EJ, Kantoff PW.The Prognostic Significance of Plasma Chromogranin A Levels in Hormone-Refractory Prostate Cancer Patients Treated on Cancer and Leukemia Group
• Oh WK, Hagmann E, Manola J, George DJ, Gilligan TD, Jacobson JO, Smith MR, Kaufman DS, Kantoff PW.A Phase I Study of estramustine, weekly docetaxel and carboplatin chemotherapy in patients with hormone refractory prostate cancer.Clinical Cancer Research.:
• Platz EA, Leitzmann MF, Rifai N, Kantoff PW, Chen K, Stampfer MJ, Willett WC, Giovannucci E.Sex steroid hormones and the androgen receptor gene CAG repeat and subsequent risk of prostate cancer in the PSA era.Cancer epidemiology, biomarkers & preventi
• Wang X,Yu J,Sreekumar A,Varambally S,Shen R,Giacherio D,Mehra R,Montie JE,Pienta KJ,Sanda MG,Kantoff PW,Rubin MA,Wei JT,Ghosh D,Chinnaiyan AM.Autoantibody signatures in prostate cancer.N Engl J Med. 2005 Sep 22;353(12):1224-35.
  16177248
• Li H, Kantoff PW, Giovannucci E, Leitzmann MF, Gaziano JM, Stampfer MJ, Ma J.Manganese superoxide dismutase polymorphism, prediagnostic antioxidant status, and risk of clinical significant prostate cancer.Cancer Res. 2005 Mar 15;65(6):2498-504.
  15781667
• Smith MR, Manola J, Kaufman DS, George D, Oh WK, Mueller E, Slovin S, Spiegelman B, Small E, Kantoff PW.Rosiglitazone versus placebo for men with prostate carcinoma and a rising serum prostate-specific antigen level after radical prostatectomy and/or radi
  15468186
• D'Amico AV, Manola J, Loffredo M, Renshaw AA, DellaCroce A, Kantoff PW.6-month androgen suppression plus radiation therapy vs radiation therapy alone for patients with clinically localized prostate cancer: a randomized controlled trial.JAMA. 2004 Aug
  15315996
• Majumder PK, Yeh JJ, George DJ, Febbo PG, Kum J, Xue Q, Bikoff R, Ma H, Kantoff PW, Golub TR, Loda M, Sellers WR.Prostate intraepithelial neoplasia induced by prostate restricted Akt activation: the MPAKT model.Proc Natl Acad Sci U S A. 2003 Jun 24;100(13
  12799464
• Halabi S,Small EJ,Hayes DF,Vogelzang NJ,Kantoff PW.Prognostic significance of reverse transcriptase polymerase chain reaction for prostate-specific antigen in metastatic prostate cancer: a nested study within CALGB 9583.J Clin Oncol. 2003 Feb 1;21(3):490-
  12560440
• Singh D, Febbo PG, Ross K, Jackson DG, Manola J, Ladd C, Tamayo P, Renshaw AA, D'Amico AV, Richie JP, Lander ES, Loda M, Kantoff PW, Golub TR, Sellers WR.Gene expression correlates of clinical prostate cancer behavior.Cancer Cell. 2002 Mar;1(2):203-9.
  12086878
• Kantoff PW, Halabi S, Farmer DA, Hayes DF, Vogelzang NA, Small EJ.Prognostic significance of reverse transcriptase polymerase chain reaction for prostate-specific antigen in men with hormone-refractory prostate cancer.J Clin Oncol. 2001 Jun 15;19(12):3025
  11408497
• Kantoff PW, Halabi S, Farmer DA, Hayes DF, Vogelzang NA, Small EJ.Prognostic significance of reverse transcriptase polymerase chain reaction for prostate specific antigen in men with androgen independent prostate cancer.J Clin Oncol. 06/15/2001;12(19):223
• Mueller E, Smith M, Sarraf P, Kroll T, Aiyer A, Kaufman DS, Oh W, Demetri G, Figg WD, Zhou XP, Eng C, Spiegelman BM, Kantoff PW.Effects of ligand activation of peroxisome proliferator-activated receptor gamma in human prostate cancer.Proc Natl Acad Sci U
  10984506
• D'Amico AV, Schultz D, Loffredo M, Dugal R, Hurwitz M, Kaplan I, Beard CJ, Renshaw AA, Kantoff PW.Biochemical outcome following external beam radiation therapy with or without androgen suppression therapy for clinically localized prostate cancer.JAMA.
  10979115
• Kantoff PW, Halabi S, Conaway M, Picus J, Kirshner J, Hars V, Trump D, Winer EP, Vogelzang NJ.Hydrocortisone with or without mitoxantrone in men with hormone-refractory prostate cancer: results of the cancer and leukemia group B 9182 study.J Clin Oncol. 1
  10561316
• Giovannucci E, Stampfer MJ, Krithivas K, Brown M, Dahl D, Brufsky A, Talcott J, Hennekens CH, Kantoff PW.The CAG repeat within the androgen receptor gene and its relationship to prostate cancer.Proc Natl Acad Sci U S A. 1997 Apr 1;94(7):3320-3.
  9096391
• Beard CJ, Propert KJ, Rieker PP, Clark JA, Kaplan I, Kantoff PW, Talcott JA.Complications after treatment with external-beam irradiation in early-stage prostate cancer patients: a prospective multiinstitutional outcomes study.J Clin Oncol. 1997 Jan;15(1):
  8996146